Declaration
This event is sponsored by the Pharmaceutical and Med Tech industries via Grants, Sponsorship and Exhibition packages.
Pharmaceutical companies have solely provided sponsorship through the purchase of exhibition space and/or sponsored speaker sessions with no further input into the arrangements of agenda of the meeting.
Sessions delivered with input from our sponsors will also be marked on the programme.
A full list of confirmed sponsors for the event can be found here: https://badannualmeeting.co.uk/exhibition/
Abstracts
Main Meeting Abstract Deadline – Midnight on 11 January 2027
Special Interest Groups and Concurrent Session Deadline – Midnight on 8 February 2027
Late Breaking Deadline – Midnight on 17 May 2027 (Hot Topic slots only, no publication)
Submission Frequently asked questions
- Abstract submission for the main meeting plenary sessions (including Clinicopathological Cases session)
Submission deadline – Midnight on 11th January 2027.
Abstract submission for the Special Interest Group and Sub-Committee sessions
Submission deadline – Midnight on 8th February 2027.
Abstracts Submissions for the following special interest groups will be considered for the 107th Annual Meeting:
- British Cosmetic Dermatology Group
- British Hair & Nail Society
- British Society of Cutaneous Allergy
- British Society for Dermatopathology
- British Society for Dermatological Surgery
- British Society for Geriatric Dermatology
- British Society for the Study of Vulval Disease
- British Society for Penile & Scrotal Dermatology
- British Society for Skin Care in Immunosuppressed Individuals
- British Society for Paediatric Adolescent Dermatology
- British Photodermatology Group
- Dermatology Education Session
- Historical Symposium*
- Skin Genetics Group
- Teledermatology
- AI & Digital Technology in Dermatology
- Global Health & Equity Session**
- Lymphoma Session
* Guidance to Authors of abstracts for submission to the Historic Symposium
- Suggested criteria for submission and judging of papers and posters for the BAD Historical symposium
- Significance of the work: Does it address an unanswered aspect of dermatological history, i.e. is it original? Would the result of the study change our view of the past? Would the results change our attitude to the present and future?
- Type of study: Is this a biography, a review, or an investigation stimulated by historical events? Have appropriate methods been used for the type of study? Are literature review, hypothesis, methodology and statistical analysis used as appropriate for the study?
- Analysis: Is the work just a review or summary of existing data already published in textbooks, journals or on the internet, or does it contain an analysis of these data producing original ideas?
- Presentation: Are the questions to be addressed, the results and meaning, clearly presented in the abstract. For posters, is the study clearly explained. Is there good use of visual images-slides or photographs?
- Work involved: Is the contribution of the presenter clearly delineated? For presenters who are students or trainees not yet in dermatology, is there appropriate recognition of support from senior dermatological colleagues?
- Biographies: These should be on people who have been deceased for at least 10 years
** Guidance for the Global Health & Equity Session
Global health dermatology is a discipline committed to advancing skin health for all populations worldwide, with a particular emphasis on health equity and the reduction of disparities in care. It prioritises integrated and sustainable solutions for resource-limited settings and is recognised as a public health priority by leading international organisations. The field fosters interdisciplinary collaboration—extending beyond the traditional health sciences—to address complex health challenges that require both population-based preventive strategies and individualised clinical interventions. Its scope transcends geographic boundaries, encompassing population-level research and initiatives in low- and middle-income countries, as well as efforts to improve access and outcomes for underserved communities within high-income nations.
The Abstract Selection Committee invites Members and their colleagues to submit papers for presentation at the BAD Annual Meeting in June / July 2027. Abstracts by non-members are very welcome.
There is no fee for making a submission. If your submission is accepted for presentation, then the presenting author will be required to attend the Conference and pay the appropriate registration fee. Authors who submitted to the main meeting will be notified in early February 2025 and authors who have submitted to the Special Interest Group and Sub-Committee sessions will be notified in March 2025 whether or not their abstract has been accepted.
BAD Author instructions 2027
-
1. The work to be presented must be original and not already published as a full paper or published as an abstract at a National or International meeting. If, at the time of submission to the BAD Annual Meeting, the work has been presented at or submitted to a National or International Dermatology meeting, it should be declared in the submission process. Prior presentations at the RSM, Irish, Welsh, Scottish, SWETS, NEDS Regional meetings presented should be declared but will still be considered. If the abstract is subsequently accepted at more than one meeting the BAD expects the authors to withdraw from one meeting to avoid duplicate publication. If not declared, then the abstract will be rejected and considered a serious probity issue.
2. All selected abstracts will be published in the online version of the British Journal of Dermatology.
3. An anonymous selection process will be used: therefore, please do not use identifying features such as names of authors, hospitals, medical schools, clinics or a geographic area specific to one hospital in the title or text of the abstract. Any author not adhering to these principles will have their paper rejected.
4. The body of the abstract should include a statement outlining the aim of the study, the methods used, a factual summary of results and a conclusion. If the abstract is an experimental one or a clinical trial, please state clearly the hypothesis being tested, describe quantitatively the experimental subject, and give an appropriate level of statistical data and details of any formal statistical setting. Statements such as “results will be discussed” are unacceptable.
5. Uncommon abbreviations should not be used without first being expressed in full. Essential references (not more than two) may be cited in the Vancouver style, as used in the British Journal of Dermatology, and must be included in the body of the abstract.
6. Presented data should agree with what is stated in the abstract.
7. Authors submitting to SIGs or Sub-Committee sessions can only submit the abstract to one session and not multiple sessions.
8. Authors should be aware that single case reports or small case series (less than 5) submitted to the main meeting will always be rejected. Exceptional single cases and small case series are still eligible for submission to the CPC Section.
9. It is strongly encouraged that any audits submitted should be from more than one centre and the audit loop should be closed. Audits from single centres will normally be rejected unless exceptional.
10. Declaration of financial interests: All funding must be declared. For the proper evaluation of a presentation, it is important that any factors that may influence the objectivity of the presenter are known by the audience. You are therefore required to reveal the source of any commercial funding for the work described in the abstract. This information must be given within the abstract and will therefore be published if it is accepted for presentation.
11. Those who have posters accepted in the main meeting can still submit the abstract for an oral only presentation in a Special Interest Group or Sub-Committee session. This is an option during the poster choices question of the online submission form. Authors will need to select the relevant Special Interest Group or Sub-Committee that the abstract should be considered when completing the SIG/Sub-Committee question.
- Late Breaking Submissions:
- Priority will be given to:
1. First-in-human trials
2. Phase II/III and head-to-head clinical trials
3. Large population-based epidemiologic and genetic studies
4. Cutting-edge technologies with major potential impact.
5. Biomarker studies with clear clinical relevance.
6. Basic science revealing mechanisms of disease, treatments, or adverse events.
7. Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.
8. Systematic reviews and meta-analyses are generally discouraged unless there is novel insight that could potentially change practice.
9. Case-based studies and series are not appropriate for this program and will automatically be excluded from the review process.
- Priority will be given to:
- Log in to the submission system when your abstract is completed and ready to send. To log in, if you are a new user you will be asked to create an account or if you have used the system before you will be asked to register with your email address and password.
- When you click the “log in” button you will be taken to a screen from which the submission process starts. Please read the instructions on this screen carefully.
- Submitting an abstract is a multi-step process. Each step asks several questions:
- Step 1: You can copy the abstract title and abstract text from your Word document and paste it into the submission box. Please note that because of web browser limitations some scientific symbols may not paste correctly into the form – you may have to correct this by writing the name of the symbol in full, for example “beta” instead of β.
- All steps: Some questions will be mandatory. We cannot accept your abstract until these questions have been answered.
- All steps: If you do not know the answer to a question – for example you may not be sure in which category your abstract should be presented – you can skip the question and return on a later occasion to complete it.
- Final step: once you have completed this step click the ‘Submit’ button. If you have answered all the mandatory questions, then your abstract will be assigned a reference number and you will receive email confirmation. If you have not answered all the mandatory questions your abstract will be held until you return later and complete all the questions.
Please use the below to ensure you have everything correct before submitting. Please note: NO CHANGES CAN BE MADE AFTER SUBMISSION
If you want to withdraw an abstract, please email [email protected]
- Main meeting abstracts are judged by the Abstract Selection Committee.
- Each Special Interest Group/Sub-Committee will have their own Abstract Selection Committee who will judge the abstracts submitted to their session and will select the best abstracts for presentation.
Main meeting
We will email all authors in early February 2027 with details on the outcome of their submission. Please do not call the office for details until then, as we will be unable to advise before this time.
Special Interest Group and Concurrent sessions
We will email all authors in March 2027 with details on the outcome of their submission. Please do not call the office for details until then, as we will be unable to advise before this time.
All selected abstracts will be printed in the BJD Supplement online.
We will publish your abstract from the version supplied by you. Please proof read your submission very carefully.
Should you have any queries relating to your abstract then please do not hesitate to contact the conference team at [email protected]
